biontech
acquire
gmp
manufacturing
site
expand
vaccine
production
capacity
first
half
mainz
germany
globe
newswire
facility
become
one
largest
mrna
manufacturing
sites
europe
third
site
biontech
manufacturing
network
germany
expected
produce
global
supply
expected
fully
operational
first
half
annual
production
capacity
million
doses
potential
vaccine
rapid
transition
expected
due
biotechnology
drug
substance
drug
product
manufacturing
equipment
well
experienced
team
biontech
take
entire
site
currently
approximately
employees
enabling
rapid
transition
production
upon
transaction
closing
mainz
germany
september
globe
newswire
biontech
se
nasdaq
bntx
biontech
company
today
announced
signing
share
purchase
agreement
novartis
ag
basel
switzerland
acquire
gmp
certified
manufacturing
facility
marburg
germany
manufacturing
site
expand
biontech
vaccine
production
capacity
million
doses
per
year
million
doses
per
month
fully
operational
transaction
expected
close
fourth
quarter
company
plans
able
produce
million
doses
first
half
thanks
established
team
drug
substance
drug
product
manufacturing
capabilities
site
marburg
production
site
gmp
certified
manufacturing
facility
currently
employs
approximately
people
fully
equipped
production
recombinant
proteins
well
cell
gene
therapies
holds
cell
culture
labs
viral
vector
production
capabilities
potential
growth
expansion
novartis
significantly
invested
site
past
five
years
located
life
science
industry
park
home
companies
employees
total
also
provides
excellent
infrastructure
company
industrial
park
located
within
one
hour
frankfurt
airport
within
minutes
biontech
headquarters
mainz
germany
acquisition
reflects
biontech
commitment
significantly
expanding
manufacturing
capacity
order
supply
potential
vaccine
worldwide
upon
authorization
approval
working
closely
novartis
prepare
smooth
transition
look
forward
welcoming
new
members
team
tapping
impressive
skills
expertise
strategic
standpoint
new
site
bolster
vertically
integrated
business
model
manufacturing
capabilities
mrna
manufacturing
well
vaccine
formulation
said
sierk
poetting
chief
financial
officer
chief
operating
officer
biontech
acquisition
accelerate
biontech
efforts
commercial
manufacturing
capacity
produce
mrna
vaccine
candidate
program
includes
five
mrna
vaccine
candidates
currently
clinical
testing
united
states
europe
south
america
china
biontech
pfizer
evaluating
lead
candidate
global
phase
trial
facility
expected
operate
one
largest
mrna
manufacturing
sites
europe
alongside
two
biontech
existing
gmp
facilities
currently
produce
vaccine
candidates
clinical
trials
addition
least
four
pfizer
production
sites
united
states
europe
marburg
facility
expected
start
production
mrna
lnp
formulation
vaccine
first
half
pending
regulatory
authorization
approval
biontech
plans
manufacture
additional
therapeutic
vaccine
drug
candidates
plant
mrna
vaccine
antibody
cell
gene
therapy
product
candidates
support
development
diversified
cancer
infectious
disease
product
pipeline
addition
biontech
intends
use
marburg
facility
contribute
production
vaccine
global
supply
including
china
partnered
fosun
pharma
subject
regulatory
authorization
approval
marburg
facility
years
long
tradition
innovation
manufacturing
site
named
behringwerke
established
emil
von
behring
developed
antitoxin
diphtheria
tetanus
used
award
money
received
nobel
prize
medicine
finance
manufacturing
site
since
founding
behringwerke
forefront
pharmaceutical
biologic
innovation
including
production
vaccines
resulting
highly
established
infrastructure
biontech
novartis
anticipate
completing
transaction
fourth
quarter
subject
regulatory
approval
satisfaction
certain
customary
closing
conditions
presentation
announcement
available
cet
biontech
biopharmaceutical
new
technologies
next
generation
immunotherapy
company
pioneering
novel
therapies
cancer
serious
diseases
company
exploits
wide
array
computational
discovery
therapeutic
drug
platforms
rapid
development
novel
biopharmaceuticals
broad
portfolio
oncology
product
candidates
includes
individualized
therapies
innovative
chimeric
antigen
receptor
cells
checkpoint
targeted
cancer
antibodies
small
molecules
based
deep
expertise
mrna
vaccine
development
manufacturing
capabilities
biontech
collaborators
developing
multiple
mrna
vaccine
candidates
range
infectious
diseases
alongside
diverse
oncology
pipeline
biontech
established
broad
set
relationships
multiple
global
pharmaceutical
collaborators
including
genmab
sanofi
bayer
animal
health
genentech
member
roche
group
genevant
fosun
pharma
pfizer
information
please
visit
biontech
statements
press
release
contains
statements
biontech
within
meaning
private
securities
litigation
reform
act
statements
may
include
may
limited
biontech
efforts
combat
collaborations
biontech
pfizer
biontech
fosun
develop
potential
vaccine
timing
close
acquisition
marburg
facility
manufacturing
capacity
marburg
facility
timeline
marburg
facility
fully
operational
produce
ability
marburg
facility
produce
mrna
vaccine
antibody
cell
gene
therapy
product
candidates
ability
biontech
supply
quantities
support
clinical
development
approved
market
demand
including
production
estimates
timing
potential
regulatory
submissions
receipt
potential
emergency
use
authorizations
approvals
statements
press
release
based
biontech
management
current
expectations
beliefs
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
competition
create
vaccine
discussion
risks
uncertainties
see
biontech
annual
report
form
filed
sec
march
available
sec
website
information
press
release
date
release
biontech
undertakes
duty
update
information
unless
required
law
biontech
contacts
media
relations
jasmina
alatovic
media
